Trials / Terminated
TerminatedNCT01112397
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1480 | continuous daily oral capsule |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2010-04-28
- Last updated
- 2013-07-22
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01112397. Inclusion in this directory is not an endorsement.